Seattle, WA, Aug-10, 2018 — / Industry Chronicle News / —
Recombinant DNA Technology Market – Power of Genetic Engineering in Improving Lives
The global recombinant DNA technology market was valued at US$ 106.8 billion in 2017, and is expected to exhibit a robust CAGR of 7.9% over the forecast period (2017 – 2025).
Recombinant DNA technology has multidisciplinary applications which deals with important aspects of life such as health improvement and food enrichment. Various novel recombinant products have been approved by the regulatory agencies favoring the rapid launch and availability of innovative therapeutics, thus bolstering the market growth. Recombinant DNA technology has played a vital role in improving health conditions for patients diagnosed with asthma, hemophilia, and cancer by developing new vaccines and pharmaceuticals For instance, in 2015,
Get a PDF Sample of Recombinant DNA TechnologyMarket Research Report at: https://www.coherentmarketinsights.com/insight/request-sample/893
The FDA approved Nucala (mepolizumab) made by GlaxoSmithKline Plc., a humanized interleukin-5 antagonist monoclonal antibody produced by recombinant DNA technology in Chinese hamster ovary cells, to treat severe asthma, thus providing a therapeutic boon to address the rising patient pool. According to the Centers for Disease Control and Prevention (CDC), 2013, more than 22 million people in the U.S. have asthma, and there are more than 400,000 asthma-related hospitalizations annually. Also, in 2016, CSL Behring received FDA approval for Idelvion, Coagulation Factor IX, albumin fusion protein produced by recombinant DNA technology, for use in children and adults with Hemophilia B.
Recombinant DNA Technology Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. The Recombinant DNA Technology market research report is a professional and in-depth study on the current state of Recombinant DNA Technology Industry.
Key Vendors of Recombinant DNA Technology Market: Some of the major players operating in the global recombinant DNA technology market are Thermo Fisher Scientific, Inc., Biogen, Inc., Sanofi Pasteur, Merck & Co., Inc., Pfizer, Inc., Profacgen, Amgen, Inc., and Monsanto Company
Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/893
Regions of Recombinant DNA Technology market:
In the end, the report makes some important proposals for a new project of Recombinant DNA Technology Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2016-2020 global Recombinant DNA Technology industry covering all important parameters.
Recombinant DNA Technology driver
Recombinant DNA Technology challenge
Recombinant DNA Technology trend
The global recombinant DNA technology market is expected to exhibit a CAGR of 7.9% over the forecast period, owing to the robust presence of pipeline products, major research activities undertaken for the novel gene editing systems such as CRISPR and its higher potential in disease treatment
Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/893
Among product type, recombinant therapeutic proteins segment holds a dominant position in the recombinant DNA technology market, owing to the vast category of products available for treating various indications such as diabetes, cancer, hemophilia, and asthma